Haldol Decanoato

Haldol Decanoato is a prescription medication containing the active ingredient haloperidol decanoate, supplied as an intramuscular injection. It is marketed in the European Union and belongs to the butyrophenone class of antipsychotics. The formulation provides a long‑acting depot preparation that delivers haloperidol over several weeks, facilitating maintenance therapy for patients with chronic psychotic disorders. The depot injection is administered by a healthcare professional and is intended for use in adults.

Haloperidol decanoate is indicated for the long‑term management of several psychiatric conditions where oral therapy may be insufficient or adherence is a concern. It is administered by deep intramuscular injection at intervals ranging from two to four weeks, providing sustained plasma concentrations.

- Schizophrenia, including maintenance treatment after stabilization. - Acute psychotic episodes when rapid control is needed. - Manic episodes associated with bipolar disorder. - Situations requiring a depot formulation to improve compliance. - Adjunctive therapy in patients with treatment‑resistant psychosis. - Chronic psychotic disorders where oral dosing is problematic. - Patients transitioning from oral haloperidol to a long‑acting injectable regimen.

Side effects of haloperidol decanoate reflect its dopamine antagonism and may vary in frequency and severity.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort. - Weight gain or changes in appetite. - Blurred vision or ocular discomfort. - Increased prolactin levels causing menstrual changes or galactorrhea. - Fatigue or weakness. - Insomnia or disturbed sleep patterns.

Serious: - Tardive dyskinesia, a potentially irreversible movement disorder. - Neuroleptic malignant syndrome, characterized by fever, muscle rigidity, and autonomic instability. - Severe hypotension or cardiac arrhythmias. - Severe allergic reactions such as angioedema or anaphylaxis. - Elevated liver enzymes indicating possible hepatic injury. - Seizures in patients with a history of epilepsy.

When prescribing haloperidol decanoate, clinicians should evaluate patient history and monitor for specific safety concerns.

- Assess cardiovascular status, especially for QT prolongation risk. - Monitor for extrapyramidal symptoms and tardive dyskinesia during long‑term use. - Evaluate liver function before initiation and periodically thereafter. - Use caution in patients with a history of seizures or neuroleptic malignant syndrome. - Screen for endocrine effects such as hyperprolactinemia, particularly in women of childbearing age. - Consider dose adjustments in the elderly or those with renal impairment. - Avoid abrupt discontinuation to reduce risk of withdrawal or relapse.

Haloperidol decanoate may interact with other medications that affect the central nervous system or cardiac conduction, requiring careful review of a patient’s drug regimen.

Avoid: - Concurrent use with other dopamine antagonists or high‑potency antipsychotics, which can increase extrapyramidal risk. - Co‑administration with drugs that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Combining with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise haloperidol levels.

Use with caution: - Sedating agents like benzodiazepines or opioids, which may enhance central nervous system depression. - Anticholinergic medications, which can mask early signs of extrapyramidal symptoms. - CYP3A4 inducers such as carbamazepine or rifampin, which may reduce therapeutic effect.